Remdesivir

COVID-19: Highly concentrated antibody solution not effective treatment - study

The trial, backed by Dr. Anthony Fauci's NIAID, tested the combination of anti-coronavirus hyperimmune intravenous immunoglobulin and remdesivir.

 COVID-19 (illustrative)
 A health worker holds up a vial of Imdevimab, an antibody cocktail designed to produce resistance to the coronavirus disease (COVID-19), at San Giuseppe Hospital, in Albano, Italy, April 22, 2021

‘Weeks, not months:’ Scientists develop ambitious pandemic response plan

A logo is pictured on the World Health Organization (WHO) headquarters in Geneva, Switzerland.

WHO advises against Gilead's remdesivir for all hospitalized COVID-19 patients

A lab technicians holds the coronavirus disease (COVID-19) treatment drug "Remdesivir" at Eva Pharma Facility in Cairo, Egypt June 25, 2020.

Countries where remdesivir is approved or supported for treating COVID-19


Sales of first big COVID-19 drug, remdesivir, may disappoint - analysis

"A lot of people were worried about the supply and wanted to keep remdesivir for their worst-case patients."

A LAB technician works on investigational coronavirus disease treatment drug Remdesivir at Eva Pharma Facility in Cairo, Egypt, in June

Remdesivir did not cut hospital stay, mortality for COVID-19 - WHO study

The WHO did not comment on the FT report, saying the results of its study were not yet public.

Vials of investigational coronavirus disease (COVID-19) treatment drug are capped at a facility.

Study confirms benefits of using Remdesivir on COVID-19 patients

The drug is used for its ability to hinder the virus's ability to reproduce, and has been attributed to shorter hospital stays for patients receiving it in trials.

A lab technicians holds the coronavirus disease (COVID-19) treatment drug "Remdesivir" at Eva Pharma Facility in Cairo, Egypt June 25, 2020.

Antibodies, Remdesivir, Vitamin D: Unpacking Trump’s COVID-19 treatment

Trump received a single eight-gram dose of Regeneron's polyclonal antibody cocktail, REG-COV2, Conley said, and the company confirmed in a statement sent to "The Jerusalem Post."

U.S. President Trump walks to the Marine One helicopter wearing a protective face mask as he departs the White House to fly to Walter Reed National Military Medical Center

US hospitals turn down remdesivir, limit use to sickest COVID-19 patients

The Food and Drug Administration has allowed more liberal remdesivir use, but 6 out of 8 major hospital systems contacted by Reuters said they were not using it for moderate cases.

A lab technicians holds the coronavirus disease (COVID-19) treatment drug "Remdesivir" at Eva Pharma Facility in Cairo, Egypt June 25, 2020.

FDA approves expanded use of remdesivir in moderate COVID-19 patients

The drug was authorized in May for use in patients with a severe form of the illness, after trial data showed the antiviral drug helped shorten hospital recovery time.

A lab technicians holds the coronavirus disease (COVID-19) treatment drug "Remdesivir" at Eva Pharma Facility in Cairo, Egypt June 25, 2020.

Israel secures more Remdesivir to treat COVID-19 patients

Several hospitals, including Sheba Medical Center at Tel Hashomer and Rambam Medical Center in Haifa, had reported they were out.

A lab technicians holds the coronavirus disease (COVID-19) treatment drug "Remdesivir" at Eva Pharma Facility in Cairo, Egypt June 25, 2020.

Israel running low on Remdesivir, drug used in treating COVID-19 patients

“We are trying to get a hold of it,” Sheba Medical Center’s Galia Rahav told The Jerusalem Post. She said the US President Donald Trump “bought all of it and one of it is left for the whole world.”

A lab technicians holds the coronavirus disease (COVID-19) treatment drug "Remdesivir" at Eva Pharma Facility in Cairo, Egypt June 25, 2020.

Gates: COVID-19 meds should to go to those in need, not 'highest bidder'

"We need leaders to make these hard decisions about distributing based on equity, not just on market-driven factors."

Bill Gates

Gilead says additional data on remdesivir shows improved clinical recovery

Findings from the analysis of its late-stage study showed that 74.4% of remdesivir-treated patients recovered by Day 14 versus 59.0% of patients receiving standard of care, the company said.

A LAB technician works on investigational coronavirus disease treatment drug Remdesivir at Eva Pharma Facility in Cairo, Egypt, in June

Gilead's coronavirus antiviral remdesivir gets conditional EU clearance

Remdesivir is in high demand after the intravenously-administered medicine helped to shorten hospital recovery times in a clinical trial.

Vials of investigational coronavirus disease (COVID-19) treatment drug are capped at a facility.